Anti-ATIC antibody [EPR13243-53],Abcam,AB188321
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
IP, WB, Flow Cyt (Intra)
Platform ID
BAB030695817
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Bifunctional enzyme that catalyzes the last two steps of purine biosynthesis (PubMed : 11948179, PubMed : 14756554). Acts as a transformylase that incorporates a formyl group to the AMP analog AICAR (5-amino-1-(5-phospho-beta-D-ribosyl)imidazole-4-carboxamide) to produce the intermediate formyl-AICAR (FAICAR) (PubMed : 10985775, PubMed : 11948179, PubMed : 9378707). Can use both 10-formyldihydrofolate and 10-formyltetrahydrofolate as the formyl donor in this reaction (PubMed : 10985775). Also catalyzes the cyclization of FAICAR to inosine monophosphate (IMP) (PubMed : 11948179, PubMed : 14756554). Is able to convert thio-AICAR to 6-mercaptopurine ribonucleotide, an inhibitor of purine biosynthesis used in the treatment of human leukemias (PubMed : 10985775). Promotes insulin receptor/INSR autophosphorylation and is involved in INSR internalization (PubMed : 25687571). See full target information ATIC
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.